Biocon Ltd - Company Profile
Powered by 
All the sales intelligence you need on Biocon Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Biocon Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Biocon Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Biocon Ltd (Biocon) is a biopharmaceutical company. It focuses on the research and development of therapies for the treatment of chronic conditions such as cancer, diabetes, and autoimmune diseases. It offers a range of active pharmaceutical ingredients (APIs), branded formulations, complex biologics, and biosimilars, including monoclonal antibodies (MAbs), rh-Insulin, and insulin analogs. The company also provides services, including contract manufacturing, drug licensing, research, development, and manufacturing of small and large molecules for biotechnology and pharmaceutical companies globally. It has a manufacturing facility and R&D center at BioXcell, Malaysia. The company has an operational presence in the UK, Ireland, the US, Switzerland, the UAE, and Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.
Headquarters
India
Address
20th Km, Hosur Road, Electronic City, Bengaluru, Karnataka, 560100
Website
www.biocon.com
Telephone
91 802 8082808
No of Employees
16,447
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BIOCON (NSE)
Revenue (2025)
$1.9B
10.9%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-61.9%
(2025 vs 2024)
Market Cap*
$7.5B
Net Profit Margin (2025)
XYZ
-65.7%
(2025 vs 2024)
* As of and is in US$
Biocon Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Generics: | Drug Licensing Services | Alzum Ab |
| Generic Formulations | Research and Development | RediHaler |
| Active Pharmaceutical Ingredients (APIs) | Contract Manufacturing Services | gSaxenda |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Acquisitions/Mergers/Takeovers | In June, the company acquired an equity stake in Ampin C&I Power Twelve Private Limited, a special-purpose vehicle formed for the generation and supply of solar power. |
| 2026 | Plans/Strategy | In June, Biocon Sdn. Bhd., Malaysia, announced plans to supply short-acting recombinant human insulin, insulin glargine, and insulin aspart to Duopharma (M) Sendirian Berhad for distribution, supporting continued access to insulin therapies for people with diabetes in Malaysia. |
| 2026 | Regulatory Approval | In May, Biocon Pharma Limited secured approval from Health Canada for micafungin for injection, USP, 50 mg and 100 mg. |
Competitor Comparison
| Key Parameters | Biocon Ltd | Sun Pharmaceutical Industries Ltd | Dr. Reddy's Laboratories Ltd | Cipla Ltd | Morepen Laboratories Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Bengaluru | Mumbai | Hyderabad | Mumbai | Gurugram |
| State/Province | Karnataka | Maharashtra | Telangana | Maharashtra | Haryana |
| No. of Employees | 16,447 | 47,000 | 27,527 | 31,369 | 1,814 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kiran Mazumdar-Shaw | Chairman | Executive Board | 2020 | 73 |
| Shreehas Pradeep Tambe | Chief Executive Officer; Managing Director | Senior Management | 2026 | - |
| Kedar Narayan Upadhye | Chief Financial Officer | Senior Management | 2026 | - |
| Arun Kumar Gupta | Chief Operating Officer | Senior Management | 2023 | - |
| Manoj Kumar Pananchukunnath | Chief Scientific Officer | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer